Myocardial fibrosis is unaltered by long-term administration of L-arginine in dystrophin deficient mdx mice: A histomorphometric analysis

Acta Biologica Hungarica

Volumn 61, Issue 2, 2010, Pages 168-174

  Marques, Maria ^a   Barbin, Isabel ^a   Taniguti, Ana ^a   Oggian, Daniela ^a   Ferretti, R ^a   Santo Neto, H ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Cardiac failure; Cardiac fibrosis; Cardiomyopathy; Duchenne muscular dystrophy

Indexed keywords

ARGININE; DRINKING WATER; DYSTROPHIN; EOSIN; HEMATOXYLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DUCHENNE MUSCULAR DYSTROPHY; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LONG TERM CARE; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; TREATMENT DURATION;

ANIMALS; ARGININE; CARDIOMYOPATHIES; DYSTROPHIN; FIBROSIS; INFLAMMATION; MALE; MICE; MICE, INBRED MDX; MUSCLES; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIUM; NITRIC OXIDE; TIME FACTORS;

ANIMALIA; MUS;

EID: 77953580338     PISSN: 02365383     EISSN: 1588256X     Source Type: Journal    
DOI: 10.1556/ABiol.61.2010.2.5     Document Type: Article

References (31)

1. Benjamin, J. (2001) Matrix metalloproteinases: from biology to therapeutic strategies in cardiovascular disease. J. Investig. Med. 49, 381-397.
2. Boger, R. H. (2008) L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous? Curr. Opin. Clin. Nutr. Metab. Care 11, 55-61.
3. Brooks, W. W., Conrad, C. H., Robinson, K. G., Colucci, W. S., Bing, O. H. L. (2009) L-Arginine fails to prevent ventricular remodeling and heart failure in the spontaneously hypertensive rat. Am. J. Hypert. 22, 228-234.
4. Chamberlain, S. J., Metzger, J., Reyes, M., Townsend, D., Faulkner, A. J. (2007) Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 21, 2195-2204.
5. Chazalette, D., Hnia, K., Rivier, F, Hugon, G., Mornet, D. (2005) Alpha 7B integrin changes in mdx mouse muscles after L-arginine administration. FEBS Lett. 579, 1079-1184.
6. Donnini, S., Monti, M., Roncone, R., Morbidelli, L., Rocchigiani, M., Oliviero, S, Casella, L., Giachetti, A., Schulz, R., Zichel, M. (2008) Peroxynitrite inactivates human-tissue inhibitor of metal-loproteinase-4. FEBS Lett. 582, 1135-1140.
7. Eberhardt, W., Pfeilschifter, J. (2007) Nitric oxide and vascular remodeling: Spotlight on the kidney. Kidney Int. 72, S9-S16.
8. Finsterer, J., Stollberger, C. (2008) Primary myopathies and the heart. Scand. Cardiovasc. J. 42, 9-24.
9. Frankel, K. A., Rosser, R. J. (1976) The pathology of the heart in progressive muscular dystrophy: Epimyocardial fibrosis. Hum. Pathol. 7, 375-386.
10. Guo, X. G., Uzui, H. Y., Mizuguchi, T. H. (2008) Imidaprilat inhibits matrix metalloproteinase-2 activity in human cardiac fibroblasts induced by interleukin-1 beta via NO-dependent pathway. Int. J. Cardiol. 126, 414-420.
11. Hoffman, E. P., Brown, R. J., Kunkel, L. M. (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-928.
12. Hnia, K., Gayraud, J., Hugon, G., Ramonatxo, M., Porte, S. D. L., Matecki, S., Momet, D. (2008) L-arginine decreases inflammation and modulates the nuclear factor-kappa B/matrix metalloproteinase cascade in mdx muscle fibers. Am. J. Pathol. 172, 1509-1519.
13. Markham, L. W., Spicer, R. L., Khoury, P. R., Wong, B. L., Mathews, K. D., Cripe, L. H. (2005) Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr. Cardiol. 26, 768-771.
14. Marques, M. J., Oggiam, D. S., Barbin, I. C. C., Ferretti, R., Santo Neto, H. (2009) Long-term therapy with deflazacort decreases myocardial fibrosis in mdx mice. Muscle Nerve 40, 466-468.
15. McCarthy, S. M., Bove, P. F., Matthews, D. E. (2008) Nitric oxide regulation of MMP-9 activation and its relationship to modifications of the cysteine switch. Biochemistry 47, 5832-5840.
16. Migita, K., Maeda, Y., Abiru, S. (2005) Peroxynitrite-mediated matrix metalloproteinase-2 activation in human hepatic stellate cell. FEBS Lett. 579, 3119-3125.
17. Morbidelli, L., Donini, S., Ziche, M. (2003) Role of nitric oxide in the modulation of angiogenesis. Curr Pharm. Des. 9, 521-530.
18. Nigro, G., Comi, L. L., Politano, L., Bain, R. J. I. (1990) The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int. J. Cardiol. 26, 271-277.
19. Pacher, P., Beckman, J. S., Liaudet, L. (2007) Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87, 315-324.
20. Quinlan, J., Hahn, H., Wong, B., Lorenz, J., Wenisch, A., Levin, L. (2004) Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul. Disord 14, 491-496.
21. Santo Neto, H., Vomero, V. U., Marques, M. J. (2006) L-arginine enhances muscle regeneration after experimental envenomation by B. jararacussu: A future for nitric oxide-based therapy? Toxicon 48, 353-357.
22. Simko, F., Luptak, I., Matuskova, J., Krajcirovicova, K., Sumbalova, Z., Kucharska, J., Gvozdjakova, A., Simko, J., Babal, P., Pechanova, O., Bernatova, I. (2005) L-arginine fails to protect against myocardial remodeling in L-NAME-induced hypertension. Eur. J. Clin. Invest. 35, 362-368.
23. Spinale, F. G. (2002) Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ. Res. 90, 520-530.
24. Spinale, F. G. (2007) Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev. 87, 1285-1342.
25. Spurney, C. F., Knoblach, S., Pistilli, E. E., Nagaraju, K, Martin, G. R., Hoffman, E. P. (2008) Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul. Disor 18, 371-381.
26. Thomas, D. D., Ridnour, L. A., Isenberg, J. S., Flores-Santana, W., Switzer, C. H., Donzelli, S., Hussain, P., Vecoli, C., Paolocci, N., Ambs, S., Colton, C. A., Harris, C. C., Roberts, D. D., Wink, D. A. (2008) The chemical biology of nitric oxide: Implications in cellular signaling. Free Radic. Biol. Med 45, 18-31.
27. van Erp, C., Hoey, A. (2004) Effect of L-arginine on cardiac function in mdx mice. J. Mol. Cel. Cardiol. 37, 170-171.
28. Wehling-Henricks, M., Jordan, M. C., Roos, K. P., Deng, B., Tidball, J. G. (2005) Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum. Mol. Genet. 14, 1921-1933.
29. Williams, I. A., Allen, D. G. (2007) The role of reactive oxygen species in the hearts of dystrophin-deficient mdx mice. Am. J. Physiol. Heart Circ. Physiol. 293, 1969-1977.
30. Wilson, A. M., Harada, R., Nair, N., Balasubramanian, N., Cooke, J. P. (2007) L-arginine supplementation in peripheral arterial disease - No benefit and possible harm. Circulation 116, 188-195.
31. Zanotti, S., Saredi, S., Ruggieri, A., Fabbri, M., Blasevich, F., Romaggi, S., Morandi, L., Mora, M. (2007) Altered extracellular matrix transcript expression and protein modulation in primary Duchenne muscular dystrophy myotubes. Matrix Biol. 26, 615-624.